Skip to main content
. Author manuscript; available in PMC: 2018 Apr 1.
Published in final edited form as: Eur Urol. 2016 Oct 4;71(4):570–581. doi: 10.1016/j.eururo.2016.09.032

Table 1.

Baseline characteristics of eligible comparative effectiveness trials

Study, [reference]/location Intervention (daily dosage) Control (daily dosage) No. randomized Duration (wk) Mean Age (yr) Mean I-PSS
Alpha-blockers, silodosin versus tamsulosin
 Takeshita (2016) [21]/Japan Silodosin 4 mg Tamsulosin 0.2 mg     34 4 wksa 70 16
 Manjunatha (2016) [22]/India Silodosin 8 mg Tamsulosin 0.4 mg     60 12 wks 64 19
 Pande (2014) [13]/India Silodosin 8 mg Tamsulosin 0.4 mg     61 12 wk 62 18
 Chapple (2011) [18]/Europe Silodosin 8 mg Tamsulosin 0.4 mg   765 12 wk 66 19
 Yokoyama (2012) [14]/Japan Silodosin 8 mg Tamsulosin 0.2 mg     46 12 wka 69 20
 Watanabe (2011) [17]/Japan Silodosin 8 mg Tamsulosin 0.2 mg   102 4 wka 70 17
 Yokoyama (2011) [16]/Japan Silodosin 8 mg Tamsulosin 0.2 mg     90 12 wk 71 18
 Yu (2011) [15]/Taiwan Silodosin 8 mg Tamsulosin 0.2 mg   209 12 wk 66 20
 Miyakita (2010) [19]/Japan Silodosin 8 mg Tamsulosin 0.2 mg     65 4 wka 69 17
 Kawabe (2006) [20]/Japan Silodosin 8 mg Tamsulosin 0.2 mg   367 12 wk 66 17
Totals and means 1799 67 18
Anticholinergics, fesoterodine plus alpha-blocker versus alpha-blocker monotherapy
 Konstantinidis (2013) [26]/Greece Fesoterodine 4 mg ER +/vs Tamsulosin 0.4 mg     47 4 wk 64 16
 Kaplan (2011) [25]/Multinational Fesoterodine 4 mg +/vs Various   943 12 wk 66 19
Totals and means   990 66 19
Anticholinergics, solifenacin plus alpha-blocker versus alpha-blocker tamsulosin monotherapy
 Van Kerrebroeck (SATURN) (2013) [33]/Europe Solifenacin 3–9 mg +/vs Tamsulosin 0.4 mg OCAS   715 12 wk 65 18
 Van Kerrebroeck (NEPTUNE) [32] (2013)/Europe Solifenacin 6–9 mg +/vs Tamsulosin 0.4 mg OCAS   993 12 wk 65 19
 Kaplan (2009) [29]/USA Solifenacin 5 mg +/vs Tamsulosin 0.4 mg   398 12 wk 65 17
 Ko (2014) [28]/Korea Solifenacin 5 mg +/vs Tamsulosin 0.2 mg   187 12 wk 61 19
 Lee (2014) [30]/Korea Solifenacin 5 mg +/vs Tamsulosin 0.2 mg   156 12 wk 61 18
 Seo (2011) [31]/Korea Solifenacin 5 mg +/vs Tamsulosin 0.2 mg     60 12 wk 58 18
 Yamaguchi (2011) [34]/Japan Solifenacin 2.5–5 mg +/vs Tamsulosin 0.2 mg   638 12 wk 70 14
Totals and means 3147 66 17
Anticholinergics, tolterodine plus alpha-blocker versus alpha-blocker monotherapy
 Memon (2014) [38]/India Tolterodine 4 mg +/vs. Alfuzosin 10 mg     70 12 wk 62 24
 Lee (2011) [37]/Korea Tolterodine 4 mg ER +/vs Doxazosin 4 mg GITS   176 12 wk 61 21
 Chapple (2009) [35]/Multinationalb Tolterodine 4 mg ER +/vs Various   652 12 wk 65 19
 Kaplan (2006) [36]/USA Tolterodine 4 mg ER +/vs Tamsulosin 0.4 mg   440 12 wk 61 20
Totals and means 1338 63 20
Phosphodiesterase type 5 inhibitors, tadalafil versus alpha-blocker tamsulosin monotherapy
 Oelke (2012) [43]/Multinational Tadalafil 5 mg Tamsulosin 0.4 mg   339 12 wk 64 17
 Yokoyama (2013) [42]/Asia Tadalafil 2.5–5 mg Tamsulosin 0.2 mg   458 12 wk 63 17
 Kim (2011) [44]/Korea Tadalafil 5 mg Tamsulosin 0.2 mg   100 12 wk 61 17
 Singh (2014) [41]/India Tadalafil 10 mg Tamsulosin 0.4 mg     89 12 wk 61 21
Totals and means   986 63 17
Phosphodiesterase type 5 inhibitors, tadalafil versus alpha-blocker monotherapy
 Kumar (2014) [45]/India Tadalafil 10 mg Alfuzosin 10 mg     50 12 wk 62 18
 Liguori (2009) [46]/Italy Tadalafil 20 mg (taken alternated d) Alfuzosin 10 mg ER     43 12 wk 61 15
Totals and means     93 62 16

ER = extended release; GITS = gastrointestinal therapeutic system; I-PSS = International Prostate Symptom Score; OCAS = oral controlled absorption system; vs = versus.

a

Crossover study, first phase presented only.

b

Includes several continents.